Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861568 | 0.84 | RAB9A (0.52) | MEN1KMT2AGPR183SMN1; SMN2KDM4E | |
| SCHEMBL16329717 | 0.83 | MEN1 (0.47) | MEN1KMT2AGPR183SMN1; SMN2ALDH1A1 | |
| SCHEMBL5379969 | 0.81 | ALDH1A1 (0.51) | MEN1KMT2AGPR183SMN1; SMN2ALDH1A1 | |
| SCHEMBL5204866 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AGPR183SMN1; SMN2ALDH1A1 | |
| SCHEMBL10428878 | 0.78 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7920809 | 0.76 | CA12 (0.48) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10428889 | 0.74 | KMT2A (0.47) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7567610 | 0.74 | RARB (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4656696 | 0.73 | CYP3A4 (0.45) | ALDH1A1HSD17B10 | |
| SCHEMBL3671715 | 0.73 | ATM (0.50) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | MEN1 2219/4885KMT2A 15/4885GPR183 2787/4885 |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | FPR1, FPR2, FPR3 | MEN1 797/4885KMT2A 4313/4885GPR183 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.